Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117190) titled 'Study on the Efficacy and Safety of Short-Course Telitacicept in Sjogren's Syndrome' on Jan. 21.

Study Type: Interventional study

Study Design: Case-Control study

Primary Sponsor: The First Affiliated Hospital of Nanchang University

Condition: Sjogren's Syndrome

Intervention: Experimental Group:Experimental Group: Telitacicept 160mg subcutaneously injected once weekly for 12 consecutive weeks, followed by drug withdrawal and continued follow-up until Week 24.

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2025-08-01

Target Sample Size: Experimental Group:30;Control Group:30;

C...